Hydal

Hydal is a prescription medication that contains hydromorphone hydrochloride, an opioid analgesic, provided in an oral dosage form. It is marketed in the European Union and is classified as a controlled prescription drug. Hydal is used under medical supervision for the management of pain that is moderate to severe, where alternative treatments are insufficient. The product’s strength and specific formulation details are determined by the prescribing physician.

Hydal is indicated for several types of pain that require strong opioid therapy. It is typically prescribed when other analgesics are inadequate.

- Management of moderate to severe acute pain, such as postoperative pain. - Treatment of chronic cancer‑related pain. - Relief of severe breakthrough pain in patients already on opioid therapy. - Use in palliative care settings for symptom control. - Short‑term control of severe musculoskeletal pain when non‑opioid options are ineffective.

Hydal may cause a range of adverse reactions, some of which are more frequently observed than others.

Common: - Constipation - Nausea and vomiting - Drowsiness or sedation - Dizziness - Dry mouth - Sweating

Serious: - Respiratory depression - Severe hypotension - Allergic reactions (rash, itching, swelling) - Dependence or withdrawal syndrome - Severe confusion or delirium

Before starting Hydal, patients should be evaluated for factors that may increase risk of adverse outcomes.

- Assess for a history of respiratory disorders, such as sleep apnea or chronic obstructive pulmonary disease. - Use caution in patients with severe hepatic or renal impairment. - Avoid use during pregnancy or breastfeeding unless clearly indicated. - Monitor for signs of opioid dependence, tolerance, or misuse. - Adjust dose in elderly patients due to increased sensitivity. - Counsel patients about the risk of constipation and provide preventive measures.

Hydal can interact with several other medications, affecting its safety and efficacy.

Avoid: - Concurrent use with other central nervous system depressants (e.g., benzodiazepines, barbiturates, alcohol). - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which may increase hydromorphone levels. - MAO inhibitors, due to risk of severe serotonin syndrome.

Use with caution: - Mixed agonist‑antagonist opioids (e.g., buprenorphine) which may precipitate withdrawal. - CNS stimulants that may mask sedation. - Medications that prolong QT interval, requiring cardiac monitoring. - Drugs that affect renal or hepatic function, potentially altering drug clearance.